IDYA
Price
$34.71
Change
-$1.41 (-3.90%)
Updated
Oct 23 closing price
Capitalization
3.35B
10 days until earnings call
Intraday BUY SELL Signals
MLTX
Price
$11.85
Change
-$0.49 (-3.97%)
Updated
Oct 23 closing price
Capitalization
1.01B
11 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IDYA vs MLTX

IDYA vs MLTX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
IDYA vs. MLTX commentary
Oct 24, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a Hold and MLTX is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for IDYA with price predictions
Oct 23, 2026

IDYA's RSI Oscillator recovers from oversold territory

The RSI Oscillator for IDYA moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 33 similar instances when the indicator left oversold territory. In 31 of the 33 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for IDYA just turned positive on October 22, 2026. Looking at past instances where IDYA's MACD turned positive, the stock continued to rise in 43 of 49 cases over the following month. The odds of a continued upward trend are 88%.

Following a +2.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where IDYA advanced for three days, in 218 of 290 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.

IDYA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 40 of 61 cases where IDYA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 66%.

The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IDYA as a result. In 82 of 110 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.

IDYA moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for IDYA crossed bearishly below the 50-day moving average on October 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDYA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.

The Aroon Indicator for IDYA entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.794) is normal, around the industry mean (3.043). P/E Ratio (-18.078) is within average values for comparable stocks, (-1.361). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (14.409) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 38 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. IDYA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is 82 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IDYA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
a Summary for MLTX with price predictions
Oct 23, 2026

MLTX's RSI Oscillator ascending out of oversold territory

The RSI Oscillator for MLTX moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 15 similar instances when the indicator left oversold territory. In 13 of the 15 cases the stock moved higher. This puts the odds of a move higher at 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 68 cases where MLTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.

The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on MLTX as a result. In 85 of 108 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.

The Moving Average Convergence Divergence (MACD) for MLTX just turned positive on October 20, 2026. Looking at past instances where MLTX's MACD turned positive, the stock continued to rise in 39 of 51 cases over the following month. The odds of a continued upward trend are 76%.

Following a +19.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where MLTX advanced for three days, in 257 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Bearish Trend Analysis

The 50-day moving average for MLTX moved below the 200-day moving average on September 17, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MLTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.

MLTX broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for MLTX entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.355) is normal, around the industry mean (3.043). P/E Ratio (-3.086) is within average values for comparable stocks, (-1.361). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. MLTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 96 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MLTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
IDYA vs MLTX: Fundamental Ratings
IDYA
MLTX
OUTLOOK RATING
1..100
664
VALUATION
overvalued / fair valued / undervalued
1..100
10
Undervalued
38
Fair valued
PROFIT vs RISK RATING
1..100
8296
SMR RATING
1..100
9498
PRICE GROWTH RATING
1..100
4863
P/E GROWTH RATING
1..100
3814
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IDYA's Valuation (10) in the null industry is in the same range as MLTX (38). This means that IDYA’s stock grew similarly to MLTX’s over the last 12 months.

IDYA's Profit vs Risk Rating (82) in the null industry is in the same range as MLTX (96). This means that IDYA’s stock grew similarly to MLTX’s over the last 12 months.

IDYA's SMR Rating (94) in the null industry is in the same range as MLTX (98). This means that IDYA’s stock grew similarly to MLTX’s over the last 12 months.

IDYA's Price Growth Rating (48) in the null industry is in the same range as MLTX (63). This means that IDYA’s stock grew similarly to MLTX’s over the last 12 months.

MLTX's P/E Growth Rating (14) in the null industry is in the same range as IDYA (38). This means that MLTX’s stock grew similarly to IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IDYAMLTX
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
87%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
66%
Bullish Trend 1 day ago
79%
Momentum
ODDS (%)
Bearish Trend 1 day ago
75%
Bullish Trend 1 day ago
79%
MACD
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
76%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
74%
Advances
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 8 days ago
76%
Bearish Trend 10 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
85%
Aroon
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
82%
COMPARISON
Comparison
Oct 24, 2026
Stock price -- (IDYA: $34.71 vs. MLTX: $11.85)
Brand notoriety: IDYA and MLTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 142% vs. MLTX: 101%
Market capitalization -- IDYA: $3.35B vs. MLTX: $1.01B
IDYA [@Biotechnology] is valued at $3.35B. MLTX’s [@Biotechnology] market capitalization is $1.01B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $132.8B. The average market capitalization across the [@Biotechnology] industry is $2.11B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 1 FA rating(s) are green while MLTX’s FA Score has 1 green FA rating(s).

  • IDYA’s FA Score: 1 green, 4 red.
  • MLTX’s FA Score: 1 green, 4 red.
According to our system of comparison, IDYA is a better buy in the long-term than MLTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 4 TA indicator(s) are bullish while MLTX’s TA Score has 5 bullish TA indicator(s).

  • IDYA’s TA Score: 4 bullish, 6 bearish.
  • MLTX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, MLTX is a better buy in the short-term than IDYA.

Price Growth

IDYA (@Biotechnology) experienced а +5.66% price change this week, while MLTX (@Biotechnology) price change was +24.08% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.24%. For the same industry, the average monthly price growth was -16.30%, and the average quarterly price growth was -16.78%.

Reported Earning Dates

IDYA is expected to report earnings on Nov 03, 2026.

MLTX is expected to report earnings on Nov 04, 2026.

Industries' Descriptions

@Biotechnology (+1.24% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
IDYA
Daily Signal:
Gain/Loss:
MLTX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SLE5.850.28
+5.03%
Super League Enterprise Inc.
BBSI33.220.41
+1.25%
Barrett Business Services Inc.
WHF7.960.01
+0.13%
WhiteHorse Finance
KHC24.80-0.29
-1.16%
Kraft Heinz Company (The)
ALK34.40-0.98
-2.77%
Alaska Air Group